Altering gene expression in modified T cells and uses thereof
US-11208661-B2 · Dec 28, 2021 · US
Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes · Cooperative Patent Classification (CPC)
Agriculture, food, personal care, health, and life sciences.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | A61K35/26 |
| Official title | Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes |
| Display label | Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes |
| Total patents | 123 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 12 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 11 |
| 2019 | 11 |
| 2020 | 4 |
| 2021 | 15 |
| 2022 | 21 |
| 2023 | 7 |
| 2024 | 13 |
| 2025 | 10 |
| 2026 | 6 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Immune stimulatory function and anti-tumor activity of TGF-β primed myeloid derived suppressor cells (MDSC)
US-11090333-B2 · Aug 17, 2021 · US
Bioengineering tertiary lymphoid structures using chitosan-based hydrogels
US-2021220441-A1 · Jul 22, 2021 · US
Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
US-11020431-B2 · Jun 1, 2021 · US
Genetically modified cells, tissues, and organs for treating disease
US-10993419-B2 · May 4, 2021 · US
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US-10918668-B2 · Feb 16, 2021 · US
CAR expression vector and CAR-expressing T cells
US-10906984-B2 · Feb 2, 2021 · US
Adiponectin-expressing regulatory t-cell precursors, composition and methods thereof
US-2021008117-A1 · Jan 14, 2021 · US
Methods and compositions for modulating thymic function
US-2021000921-A1 · Jan 7, 2021 · US
Altering Gene Expression in CART Cells and Uses Thereof
US-2020407728-A1 · Dec 31, 2020 · US
Genetically modified cells, tissues, and organs for treating disease
US-2020352142-A1 · Nov 12, 2020 · US
Therapeutic heterocyclic compounds
US-2020316035-A1 · Oct 8, 2020 · US
Isolation and use of human lymphoid organ-derived suppressive stromal cells
US-2020061118-A1 · Feb 27, 2020 · US
Fat-associated lymphoid clusters as sites for transplantation, tissue regeneration, organogenesis and function for multiple tissues
US-2019374583-A1 · Dec 12, 2019 · US
Car expression vector and car-expressing t cells
US-2019322755-A1 · Oct 24, 2019 · US
Isolation and use of human lymphoid organ-derived suppressive stromal cells
US-10420801-B2 · Sep 24, 2019 · US
Genetically modified cells, tissues, and organs for treating disease
US-2019254265-A1 · Aug 22, 2019 · US
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
US-2019255111-A1 · Aug 22, 2019 · US
Therapeutic heterocyclic compounds
US-2019192504-A1 · Jun 27, 2019 · US
Car expression vector and car-expressing T cells
US-10316102-B2 · Jun 11, 2019 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC A61K35/26?
- CPC A61K35/26 is the Cooperative Patent Classification code for “Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes.”
- How many patents are filed under CPC A61K35/26 (Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes)?
- Our database includes 123 publications tagged with this CPC code.
- Is patent activity under CPC A61K35/26 growing?
- Publication counts under this code: 13 in 2024 vs 10 in 2025 (latest complete years).